Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
2022 · Nature Medicine · 379 citations
https://doi.org/10.1038/s41591-022-01935-8
E
Elisabeth Bergen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
83
Papers
1.0K
Citations
15
h-index
18
i10-index
Elisabeth Bergen is an academic researcher from Université Paris Cité. The author has contributed to research in topics: Brain Metastases and Treatment & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 15, co-authored 71 publications.
ORCID: 0000-0002-0374-1408Papers by this author
worksActivity of T-DM1 in Her2-positive breast cancer brain metastases
2015 · Clinical & Experimental Metastasis · 120 citations
https://doi.org/10.1007/s10585-015-9740-3
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
2024 · Neuro-Oncology · 51 citations
https://doi.org/10.1093/neuonc/noae123
ASCO 2018: highlights in HER2-positive metastatic breast cancer
2018 · memo - Magazine of European Medical Oncology · 26 citations
https://doi.org/10.1007/s12254-018-0441-x
Prognostic impact of breast cancer subtypes in elderly patients
2016 · Breast Cancer Research and Treatment · 25 citations
https://doi.org/10.1007/s10549-016-3787-y
Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
2021 · ESMO Open · 18 citations
https://doi.org/10.1016/j.esmoop.2021.100168
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat